<DOC>
	<DOCNO>NCT02317991</DOCNO>
	<brief_summary>The purpose study determine whether nab-Paclitaxel ( Abraxane速 ) ramucirumab ( Cyramza速 ) effective use combination treat patient metastatic gastroesophageal cancer either progress respond prior therapy .</brief_summary>
	<brief_title>Study Nab-Paclitaxel Ramucirumab Second-line Treatment Patients With Metastatic Gastroesophageal Cancer</brief_title>
	<detailed_description>Adenocarcinoma esophagus gastroesophageal junction ( GE junction ) ninth common cancer worldwide . Ramucirumab ( Cyramza速 ) , monoclonal antibody , approve single agent combination paclitaxel treatment patient metastatic gastric GE junction adenocarcinoma whose cancer progress prior chemotherapy . Nab-paclitaxel ( Abraxane速 ) albumin-based formulation paclitaxel develop improve therapeutic index reduce toxicity . Nab-paclitaxel approve 40 countries/regions treatment various metastatic cancer include breast cancer , non-small cell lung cancer ( NSCLC ) , pancreatic cancer . In Phase II study , investigator propose combine less toxic nab-paclitaxel increase tumor uptake drug improve efficacy minimize side effect . The biological rationale use combination ramucirumab inhibit tumor angiogenesis nab-paclitaxel induce apoptosis rapidly divide tumor cell .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Ramucirumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Patients histologically confirm metastatic adenocarcinoma esophagus , GE junction , stomach progress one prior line chemotherapy metastatic setting . 2 . Measurable disease measure Response Evaluation Criteria Solid Tumors ( RECIST ) criteria Version 1.1 . 3 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status score 0 1 4 . Adequate hematologic , renal , hepatic function 5 . Patients must &lt; Grade 2 preexist peripheral neuropathy ( per National Cancer Institute Common Terminology Criteria Adverse Events [ NCI CTCAE ] v 4.03 ) 6 . Life expectancy &gt; 3 month 1 . Patients receive investigational agent , chemotherapy , biologic therapy , radiation therapy within 28 day prior Day 1 study . For investigational , chemotherapy , biologic therapy , patient allow study five halflives great elapse since last dose drug 28 day , whichever short . 2 . Patients prior taxane chemotherapy agent act primary antiangiogenic mechanism . 3 . Uncontrolled intercurrent illness include , limited , ongoing active infection , psychiatric illness/social situation would limit safety compliance study requirement may interfere interpretation result . 4 . Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior study initiation , anticipation need major surgical procedure course study . 5 . Evidence history uncontrolled hypertension , proteinuria , nonhealing wound , ulcer , bone fracture , hemoptysis , valvular disease , abdominal fistula , GI perforation , intraabdominal abscess , bleed diathesis coagulopathy would exclude patient treatment antiangiogenesis agent . 6 . Therapeutic anticoagulation coumarinderivatives permit . However , maximum daily dose 1 mg permit port line patency . Anticoagulation low molecular weight heparin antiFactor Xa agent allow . 7 . Patients concurrent severe and/or uncontrolled medical disease could compromise safety treatment judge treat physician ( i.e. , severely impaired lung function , severe infection , ventricular arrhythmia active ischemic heart disease , know active vasculitis cause , chronic liver renal disease ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>gastroesophageal adenocarcinoma</keyword>
	<keyword>nab-paclitaxel</keyword>
	<keyword>Abraxane</keyword>
	<keyword>ramucirumab</keyword>
	<keyword>Cyramza</keyword>
	<keyword>GE junction</keyword>
</DOC>